SCAI anticorps (AA 1-549)

N° du produit ABIN7869463

Cet anticorps anti-SCAI Polyclonal Lapin (ABIN7869463) détecte spécifiquement SCAI dans WB et ELISA. L’anticorps est réactif avec des échantillons de Humain, Souris et Rat.

Aperçu rapide pour SCAI anticorps (AA 1-549) (ABIN7869463)

Antigène: SCAI (Suppressor of Cancer Cell Invasion (SCAI))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SCAI est non-conjugé

Application: Western Blotting (WB), ELISA

Détail du produit anti-SCAI anticorps

Épitope: AA 1-549

Fonction: SCAI Antibody / Suppressor of cancer cell invasion

Purification: Immunogen affinity purified

Immunogène: E.coli-derived human SCAI recombinant protein (Position: M1-A549) was used as the immunogen for the SCAI antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the SCAI antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Stock: 4 °C,-20 °C

Stockage commentaire: After reconstitution, the SCAI antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Détails sur SCAI

Antigène: SCAI (Suppressor of Cancer Cell Invasion (SCAI))

Autre désignation: SCAI

Sujet: SCAI antibody detects Suppressor of cancer cell invasion, encoded by the SCAI gene. Suppressor of cancer cell invasion is a transcriptional regulator that represses genes promoting migration and invasion, playing an important role in cancer progression and cellular motility. SCAI antibody provides researchers with a reagent for studying tumor invasion, actin cytoskeleton regulation, and metastasis.

Suppressor of cancer cell invasion functions as a transcriptional repressor by interacting with myocardin-related transcription factors and actin regulatory pathways. Research using SCAI antibody has shown that it inhibits serum response factor target genes and downregulates expression of proteins that promote actin cytoskeleton remodeling. This leads to reduced migration and invasion in cancer cells, highlighting SCAI as an invasion suppressor.

Studies with SCAI antibody have revealed that loss of SCAI enhances cancer cell invasion and metastasis. In breast and prostate cancer models, reduced expression correlates with higher invasiveness and poor prognosis. Conversely, restoration of SCAI suppresses migration, suggesting therapeutic potential. These findings underscore its importance in tumor suppression.

Beyond cancer, Suppressor of cancer cell invasion may regulate other processes involving actin dynamics. Research using SCAI antibody has suggested roles in development and wound healing, where it modulates actin-dependent transcriptional programs. This positions SCAI as a broader regulator of motility-related pathways.

Dysregulation of SCAI has been linked to multiple tumor types and correlates with aggressive phenotypes. Research using SCAI antibody has demonstrated that its downregulation is a hallmark of invasive cancers, while its presence restrains progression. These insights emphasize its potential as both a biomarker and therapeutic target.

SCAI antibody is widely applied in immunohistochemistry, western blotting, and cell migration studies. Immunohistochemistry demonstrates reduced expression in invasive cancers, western blotting quantifies levels in tumor and normal tissue, and functional assays assess its effect on motility. These applications make SCAI antibody indispensable for cancer research.

By providing validated SCAI antibody reagents, NSJ Bioreagents supports studies into invasion suppression, transcriptional regulation, and cancer biology. Detection of Suppressor of cancer cell invasion provides researchers with insight into how transcriptional repressors control migration and tumor progression.

UniProt: Q8N9R8